---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-056957"
form_type: "8-K"
ticker: null
cik: "0001173281"
company_name: "NeuBase Therapeutics, Inc."
filed_at: "2024-05-03T23:59:59+00:00"
generated_at: "2026-06-02T22:56:28.945223+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# NeuBase Therapeutics receives Nasdaq delisting notice; trading to be suspended May 13 amid planned dissolution

## Summary
- Nasdaq notified NeuBase on May 2, 2024 that it failed to regain compliance with $1.00 minimum bid price requirement.
- Company does not intend to appeal; trading suspension expected at open on May 13, 2024, followed by Form 25-NSE filing.
- Board previously approved liquidation and dissolution, subject to stockholder vote at special meeting on May 13, 2024.
- In light of planned dissolution, company will not seek an appeal of the delisting determination.

## SEC filing metadata
- accession: 0001104659-24-056957
- form_type: 8-K
- cik: 0001173281
- company_name: NeuBase Therapeutics, Inc.
- filed_at: 2024-05-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173281/000110465924056957/0001104659-24-056957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173281/000110465924056957/tm2413464d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-056957
- JSON: https://secwatch.observer/filing/0001104659-24-056957.json
- Plain text: https://secwatch.observer/filing/0001104659-24-056957.txt

## Key facts
- Listing & Compliance Notices
  NeuBase Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: May 2, 2024, the Staff notified the Company that it has not regained compliance with the Minimum Bid Price Requirement (the “Delisting Determination”) and that it is ineligible for a second 180 calendar day period to regain compliance as it did not provide information regarding its intent to cure the bid price deficiency. The Staff informed the Company that unless it requests an appeal of the Delisting Determination to a Hearings Panel by May 9, 2024, the Company’s common stock will be scheduled for delisting from the Nasdaq Capital Market and will be suspended at the opening of business on Ma
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173281/000110465924056957/0001104659-24-056957-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.